Which treatment is appropriate for moderate persistent asthma?

The appropriate treatment for moderate persistent asthma includes the combination of inhaled corticosteroids (ICS) and a long-acting beta-agonist (LABA). This treatment strategy is effective because it addresses both inflammation and bronchoconstriction, which are key components of asthma management. Inhaled corticosteroids work by reducing airway inflammation and swelling, helping to prevent asthma symptoms. The addition of a LABA provides longer-lasting bronchodilation, which can help improve airflow and reduce the frequency of symptoms.

Moderate persistent asthma is characterized by daily symptoms, and the use of ICS and LABA as a combination therapy provides better control compared to ICS alone. This combination allows for reduced dependence on rescue medications and helps patients maintain better overall asthma control.

The other options represent less optimal choices for this level of asthma severity. High doses of ICS plus LABA would generally be considered for severe asthma cases, not moderate persistent. While oral corticosteroids may be necessary for severe exacerbations, they are not typically used as a routine treatment for moderate persistent asthma due to significant side effects associated with long-term use. Finally, using a short-acting beta-agonist (SABA) alone does not provide the necessary management for moderate persistent asthma, as it only temporarily relieves